Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Princeton University

Latest From Princeton University

Declaration Of Independence: Perlstein Lab Goes Solo Against Rare Diseases

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

BioPharmaceutical United States

Declaration Of Independence: Perlstein Lab Goes Solo Against Rare Diseases

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

BioPharmaceutical United States

Deals Shaping The Medical Industry, December 2012

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

HepatoChem Inc.

Liver toxicity is the most common safety issue in new drug development. Unfortunately, existing techniques for identifying drug metabolites aren’t that reliable. As a result, drugs frequently enter clinical trials with relatively little or no metabolite data that might alert developers to potential safety problems. HepatoChem Inc. aims to improve matters for its clients with a “chemical liver” designed to mimic the oxidation that can occur during Phase I metabolism.

BioPharmaceutical Clinical Trials
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register